BriaCell Therapeutics Corp. (BCT)
TSX
Real-time Data
01:30 PM
Day's Range
4.7852 wk Range
3.68Overview - BCT - BriaCell Therapeutics Corp.
Key Statistics
Valuation
Enterprise Value
34.30M
P/E (Trailing)
‪-0.11‬
P/E (Forward)
‪-9.64‬
PEG Ratio
‪0.0011‬
Price / Book
‪1.13‬
EV / EBITDA
‪-0.78‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-90.84%‬
Return on Equity
‪-175.25%‬
Ownership
Shares Outstanding
7.25M
Float
7.85M
Short % of Shares Outstanding
‪0.16%‬
Held by Insiders
‪0.50%‬
Held by Institutions
‪6.39%‬
Price stats
Beta
‪1.51‬
50-Day Avg
‪4.79‬
200-Day Avg
‪7.08‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Market Cap - BCT - BriaCell Therapeutics Corp.
Peers - BCT - BriaCell Therapeutics Corp.
Peer Comparison
Compared with companies in Biotechnology listed on TSX.
- BCTTSXBriaCell Therapeutics Corp.48.37MMarket Cap-87.23%52-week change-0.13P/E (Trailing)‪0.00%‬Profit Margin
- APMTSXAndean Precious Metals Corp.1.08BMarket Cap+28.04%52-week change6.71P/E (Trailing)‪26.46%‬Profit Margin
- AIMTSXAimia Inc.241.29MMarket Cap-15.69%52-week change7.08P/E (Trailing)‪5.24%‬Profit Margin
- APLITSXAppili Therapeutics Inc.1.98MMarket Cap-33.33%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - BCT - BriaCell Therapeutics Corp.
About
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in developing novel immunotherapies to transform cancer care. The company focuses on cell-based cancer immunotherapies designed to harness and direct the immune system against tumors, with initial emphasis on metastatic breast cancer…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
